Bayer, Foundation Medicine to Collaborate on Cancer Test Sequencing

Collaboration will start with development of a companion diagnostic for Vitrakvi® (larotrectinib), the first and only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors; Vitrakvi is under review in other markets around the world

* Goal is to advance broad patient access to comprehensive genomic testing in line with Bayer’s commitment to precision medicine

Bayer AG and Foundation Medicine, Inc.today announced a global collaboration for the development and commercialization of NGS-based companion diagnostics. This agreement allows for collaboration across multiple oncology drug candidates and approved therapies developed by Bayer and covers Foundation Medicine’s full portfolio of tests, including FoundationOne®CDx. The first project will be to develop a companion diagnostic for Vitrakvi® (larotrectinib), the first and only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors.

https://www.marketscreener.com/BAYER-AG-436063/news/Bayer-And-Foundation-Medicine-Announce-Global-Collaboration-To-Develop-Next-generation-Sequencing-28674119/